A Phase 2 interventional study of S-606001 and Placebo in Pompe Disease, sponsored by Shionogi. Recruiting at 28 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by Shionogi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies in Glycogen Storage Disease Type II with a site in United States — 11 open to participants now, 20 under way, 3 of them phase 3. Glycogen Storage Disease Type II · United States.
Among the 93 studies in Glycogen Storage Disease Type II with a site in United States, this one is the 12th largest by planned enrollment of the 60 interventional ones that give a count, is the only one that started in 2025, is one of 12 in phase 2, reaches primary completion later than 7 of the 19 other live ones, and was the 90th registered.
162 studies on the registry are indexed under Glycogen Storage Disease Type II; 34 are open to participants now.
Browse Glycogen Storage Disease Type II studies →11 of the 93 studies in Glycogen Storage Disease Type II with a site in United States are open now. Recruiting first, the newest first:
Denali Therapeutics Inc. · Sites in United States
Ages 18–75
AskBio Inc · Sites in United States
Ages 18–65
xCures · Sites in United States
Amicus Therapeutics · Sites in United States, Austria, Belgium and 9 more countries
Amicus Therapeutics · Sites in United States, Germany, Italy and 3 more countries
Ages up to 17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 23 Glycogen Storage Disease Type II studies recruiting now, 16 (70%) set no upper age limit and 6 (26%) stop at 75 or younger; 15 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 26 · Phase 3 10 · Phase 4 9
First in 1993; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is above the median of 20 across 89 interventional studies indexed under Glycogen Storage Disease Type II.
Median enrollment 18 across the 60 interventional studies, 38 across the 30 observational. Of the 65 that completed or were terminated, 27 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 93 have an industry lead sponsor. The 10 most frequent:
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Shionogi has 3 studies filed under Glycogen Storage Disease Type II — fewer than ten, so there is no comparison to draw.
6 of the studies in Glycogen Storage Disease Type II with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03911505Phase 3Amicus TherapeuticsZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD | 2027-03 |
| NCT04808505Phase 3Amicus TherapeuticsA Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18 | 2027-07 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06150820Astellas Gene TherapiesA Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease | 2027-06-30 |
| NCT07123155ShionogiStudy of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD) | 2027-08-08 |
Add all 6 to your calendar (.ics) → With an account.
Among the 93 studies in Glycogen Storage Disease Type II with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and exploratory clinical efficacy of S-606001 in adult participants with LOPD as an add-on to ERT.
Key Inclusion Criteria:
Participant must have a diagnosis of LOPD based on documentation of 1 of the following:
Participant performs the 6MWT at screening, as determined by the clinical evaluator, and meets all of the following criteria:
Key Exclusion Criteria:
Note: Other protocol-specified inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive S-606001 at a low dose level twice daily (BID) after a meal for 52 weeks.
Drug: S-606001
Participants will receive S-606001 at a high dose level BID after a meal for 52 weeks.
Drug: S-606001
Participants will receive S-606001 matching placebo BID after a meal for 52 weeks.
Drug: Placebo
S-606001 administered orally
S-606001 matching placebo administered orally
Change From Baseline in Percent Forced Vital Capacity (%FVC) at Week 52
Time frame: Baseline, Week 52
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: Baseline up to Week 53
Plasma Concentration of S-606001
Time frame: Up to Week 12
Change From Baseline in Serum Creatine Kinase Levels at Week 52
Time frame: Baseline, Week 52
Change From Baseline in 6-minute Walk Test (6MWT) at Week 52
Time frame: Baseline, Week 52
Change From Baseline in Pulmonary Function Parameter: Maximal Inspiratory Pressure (MIP) at Week 52
Time frame: Baseline, Week 52
Change From Baseline in Pulmonary Function Parameter: Maximal Expiratory Pressure (MEP) at Week 52
Time frame: Baseline, Week 52
Change From Baseline in Motor Function Parameter: Gait, Stair, Gower's Maneuver, Chair (GSGC) Score at Week 52
Time frame: Baseline, Week 52
Change From Baseline in Patient-Reported Outcomes Measurement Information System Fatigue Short Form 8a (PROMIS-Fatigue-8a) Score at Week 52
Time frame: Baseline, Week 52
Change From Baseline in Patient-Reported Outcomes Measurement Information System Physical Function 20-item short form (PROMIS-PF-20) Score at Week 52
Time frame: Baseline, Week 52
Change From Baseline in Patient-Reported Outcomes Measurement Information System v2.0 Pain Intensity 3a (PROMIS v2.0 PAIN) Score at Week 52
Time frame: Baseline, Week 52
Change From Baseline in 36-item Short Form Health Survey (SF-36) Score at Week 52
Time frame: Baseline, Week 52
Change From Baseline in Patient Global Impression of Severity (PGI-S) Score at Week 52
Time frame: Baseline, Week 52
Started Oct 2025 (actual). Primary completion is estimated for Aug 2027, 21 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: S-606001
Glycogen Storage Disease Type II →